PDL BioPharma, Inc. (PDLI) Tops Q4 EPS 2c

March 1, 2013 4:06 PM EST Send to a Friend
PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q4 EPS of $34.00, $0.02 better than the analyst estimate of $0.32. Revenue for the quarter came in at $86 million versus the consensus estimate of $86.08 million.

For earnings history and earnings-related data on PDL BioPharma, Inc. (PDLI) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment